Every round on record, with the sources behind each and the investors on them.
They sell cancer detection tests via blood analysis, primarily targeting healthcare providers and patients requiring early detection or monitoring of cancer.
aima-diagnostics.comMeylanMedtech
2 sources · checked 4 times, last 2h ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
Source 2 fixes the announcement to 27 October; Source 1 is later. Headquarters differs: Source 2 says Meylan, while Source 1 says Grenoble; the specific legal-seat wording wins.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Levée de fonds | $2.5M 2,2 millions d'euros | 2026-10-27 | not stated | No recent discussion |
2 sources · checked 4 times, last 2h ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 2 sources Source 2 fixes the announcement to 27 October; Source 1 is later. Headquarters differs: Source 2 says Meylan, while Source 1 says Grenoble; the specific legal-seat wording wins. | ||||
None named.